RESEARCH LETTER

Expanded Newborn Screening for Detection of Vitamin B 12 Deficiency
To the Editor: When undiagnosed, infant vitamin B 12 deficiency can result in anemia, failure to thrive, developmental regression, and neurological deficits and is most commonly caused by maternal vitamin B 12 deficiency. 1 Biochemically, vitamin B 12 deficiency leads to an accumulation of total homocysteine (tHcy), methylmalonic acid (MMA), and propionylcarnitine (C 3 ). Although vitamin B 12 deficiency is not a primary target of newborn screening (NBS) programs, measurement of C 3 may incidentally identify vitamin B 12 -deficient newborns. However, first-tier screening is limited because C 3 levels may not be sufficiently high during the first days of life when most NBS samples are collected. 2 Levels of MMA and tHcy are more sensitive markers of vitamin B 12 status than serum B 12 levels in adults, 3 have a strong inverse relationship with serum B 12 levels, 4 and are usually elevated in infants who are vitamin B 12 deficient before hematologic or neurologic findings develop.
2 Through the public-private partnership between the Minnesota Department of Health, Mayo Clinic, and University of Minnesota, a lower first-tier cut-off level of C 3 was applied (Ͼ9.2 µmol/L to Ͼ5.25 µmol/L) and second-tier testing of MMA and tHcy levels in presumptive-positive NBS specimens was introduced in 2005. Methods. A population-based study of 363 649 infants born in Minnesota was conducted between January 1, 2005, and December 31, 2010. Newborn screening samples with elevated C 3 levels, a C 3 to acetylcarnitine (C 3 /C 2 ) ratio of 0.1 or greater, or a C 3 to palmitoylcarnitine (C 3 /C 16 ) ratio of 2 or greater had second-tier testing of tHcy (abnormal, Ͼ15 µmol/L) and MMA (abnormal, Ͼ5 µmol/L) on the same sample. 5 (To convert tHcy to mg/dL, divide by 7.397.) All newborns with positive NBS results and some of their mothers underwent further laboratory testing. An additional newborn from another state whose first-tier NBS findings were normal presented at age 2 months with clinical complications of vitamin B 12 deficiency and required prolonged hospitalization. His original NBS sample was retrospectively analyzed to determine if the Minnesota 2-tier protocol would have led to identifying the infant as vitamin B 12 deficient. The University of Minnesota institutional review board approved review of medical records and waived informed consent.
Results. Of 46 newborns with abnormal C 3 levels or related ratios identified in Minnesota, 11 had vitamin B 12 deficiency secondary to maternal vitamin B 12 deficiency (TABLE 1  and TABLE 2 ) for a detection rate of 3.02 per 100 000 live births; 22 findings were false positives; 1 declined follow-up testing; 1 had unconfirmed vitamin B 12 deficiency; 3 had cobalamin C defects; and 2 had methylmalonic acidemias. Five were homozygous and 1 a carrier for transcobalamin receptor defects. Newborn screening led to the identification of vitamin Abbreviations: C3, propionylcarnitine; C2, acetylcarnitine; C16, palmitoylcarnitine; IM, intramuscular; MMA, methylmalonic acid; NA, not available; tHcy, total homocysteine. SI conversion factors: To convert serum B12 to pmol/L, multiply by 0.7378; to convert tHcy to mg/dL, divide by 7.397. a Maternal vitamin B12 deficiency was defined by low serum B12 maternal levels or low serum B12 levels in the infants on confirmatory testing and if their initial elevated urine MMA or plasma tHcy normalized while receiving vitamin B12 supplementation or remained normal after discontinuing vitamin B12 therapy. Another cause of low B12 levels, cobalamin F deficiency, is unlikely due to positive clinical response to oral vitamin B12 therapy or normalization of biochemical markers while not receiving treatment. In case 5, for which serum B12 levels were not available in the infant or mother, elevated markers of MMA and tHcy indicated functional vitamin B12 deficiency as they normalized after treatment. b Serum B12 levels were abnormal if Ͻ211 pg/mL. Percentiles (1st-99th) for C3 based on 469 279 newborn screening samples analyzed. 5 Levels of C3 were abnormal if Ͼ5.25 µmol/L (range, 0.6-5.1 µmol/L). C3/C2 ratio was abnormal if Ն0.1, and C3/C16 ratio was abnormal if Ն2. B 12 deficiency in 8 of 11 mothers whose status was previously unrecognized. All 11 newborns were asymptomatic when treatment was initiated (Table 2) , and subsequently all biochemical markers normalized without clinical signs of vitamin B 12 deficiency. Retrospective analysis using the 2-tier protocol of the original NBS sample of the symptomatic infant screened by another state had positive results (Table 1, case 12) .
Comment. A recent survey of 12 state NBS programs (including Minnesota) identified 32 cases of nutritional vitamin B 12 deficiency, for a rate of 0.88 per 100 000 newborns. 6 After implementing a lower C 3 first-tier cut-off level and second-tier testing of MMA and tHcy levels in NBS specimens, the detection rate in Minnesota of vitamin B 12 -deficient infants was considerably higher (3.02/100 000 live births). None of the 11 infants would have been identified by using the previous C 3 cut-off value, potentially explaining the reason no cases of infant vitamin B 12 deficiency were identified by NBS before 2005 in Minnesota.
Based on the Minnesota experience, vitamin B 12 deficiency occurs more frequently than is currently recognized. Given the important role vitamin B 12 plays in DNA synthesis and central nervous system function, and the difficulty in diagnosing vitamin B 12 deficiency in infancy because of nonspecific clinical findings, early identification and initiation of treatment are crucial to avoid potentially devastating and irreversible neurologic damage.
